Incidence, Predictors, and Impact on Survival of Left Ventricular Systolic Dysfunction and Recovery in Advanced Cancer Patients

5.00
Hdl Handle:
http://hdl.handle.net/10757/320254
Title:
Incidence, Predictors, and Impact on Survival of Left Ventricular Systolic Dysfunction and Recovery in Advanced Cancer Patients
Authors:
Oliveira, Guilherme H.; Mukerji, Siddarth; Hernández, Adrian V. ( 0000-0002-9999-4003 ) ; Qattan, Marwan Y.; Banchs, Jose; Durand, Jean-Bernard; Iliescu, Cezar; Plana, Juan Carlos; Tang, W.H. Wilson
Publisher:
Elsevier B.V.
Journal:
American Journal of Cardiology
Issue Date:
9-Jun-2014
URI:
http://hdl.handle.net/10757/320254
DOI:
10.1016/j.amjcard.2014.03.018
Additional Links:
http://www.sciencedirect.com/science/article/pii/S000291491400808X
Abstract:
Although left ventricular (LV) dysfunction occurs not uncommonly in the course of cancer therapy, little is known about its natural history and prognostic impact on patients. To investigate the incidence, predictors, and impact on survival of LV systolic dysfunction and recovery during cancer therapy, we conducted a retrospective cohort observational study over 1 year at the University of Texas MD Anderson Cancer Center. We enrolled patients with a decrease in ejection fraction by echocardiography to <50% while undergoing cancer therapy from January 2009 to December 2009.We collected and analyzed their chart data. Of 7,648 patients with echocardiograms in 2009, 366 (4.8%) had ejection fraction <50% and 104 met study criteria. LV systolic dysfunction was associated with cardiotoxic therapy in 53 patients (51%). Recovery occurred in 57 patients (55%) and was independently predicted by younger age, smaller left atrial volume index, and lower B-type natriuretic peptide. At last follow-up, 69 patients (66%) were dead, and 35 (34%) were alive. There was a 20% advantage in 2-year survival among patients with LV systolic recovery compared with those without (95% confidence interval 4% to 41%, p [ 0.02). In this retrospective study, LV systolic dysfunction recovery occurred in over half of the patients, appeared independent of cardiotoxic etiology, and associated with a 20% survival benefit at 2 years. Multivariable predictors of recovery are younger age, a small left atrial volume index, and lower B-type natriuretic peptide.
Type:
info:eu-repo/semantics/article
Rights:
info:eu-repo/semantics/openAccess
Language:
eng
ISSN:
0002-9149
EISSN:
1879-1913

Full metadata record

DC FieldValue Language
dc.contributor.authorOliveira, Guilherme H.es_PE
dc.contributor.authorMukerji, Siddarthes_PE
dc.contributor.authorHernández, Adrian V.es_PE
dc.contributor.authorQattan, Marwan Y.es_PE
dc.contributor.authorBanchs, Josees_PE
dc.contributor.authorDurand, Jean-Bernardes_PE
dc.contributor.authorIliescu, Cezares_PE
dc.contributor.authorPlana, Juan Carloses_PE
dc.contributor.authorTang, W.H. Wilsones_PE
dc.date.accessioned2014-06-10T01:13:06Z-
dc.date.available2014-06-10T01:13:06Z-
dc.date.issued2014-06-09-
dc.identifier.issn0002-9149-
dc.identifier.doi10.1016/j.amjcard.2014.03.018-
dc.identifier.urihttp://hdl.handle.net/10757/320254es_PE
dc.description.abstractAlthough left ventricular (LV) dysfunction occurs not uncommonly in the course of cancer therapy, little is known about its natural history and prognostic impact on patients. To investigate the incidence, predictors, and impact on survival of LV systolic dysfunction and recovery during cancer therapy, we conducted a retrospective cohort observational study over 1 year at the University of Texas MD Anderson Cancer Center. We enrolled patients with a decrease in ejection fraction by echocardiography to <50% while undergoing cancer therapy from January 2009 to December 2009.We collected and analyzed their chart data. Of 7,648 patients with echocardiograms in 2009, 366 (4.8%) had ejection fraction <50% and 104 met study criteria. LV systolic dysfunction was associated with cardiotoxic therapy in 53 patients (51%). Recovery occurred in 57 patients (55%) and was independently predicted by younger age, smaller left atrial volume index, and lower B-type natriuretic peptide. At last follow-up, 69 patients (66%) were dead, and 35 (34%) were alive. There was a 20% advantage in 2-year survival among patients with LV systolic recovery compared with those without (95% confidence interval 4% to 41%, p [ 0.02). In this retrospective study, LV systolic dysfunction recovery occurred in over half of the patients, appeared independent of cardiotoxic etiology, and associated with a 20% survival benefit at 2 years. Multivariable predictors of recovery are younger age, a small left atrial volume index, and lower B-type natriuretic peptide.es_PE
dc.formatapplication/pdfes_PE
dc.language.isoenges_PE
dc.publisherElsevier B.V.es_PE
dc.relation.urlhttp://www.sciencedirect.com/science/article/pii/S000291491400808Xes_PE
dc.rightsinfo:eu-repo/semantics/openAccesses_PE
dc.sourceUniversidad Peruana de Ciencias Aplicadas (UPC)es_PE
dc.sourceRepositorio Académico - UPCes_PE
dc.titleIncidence, Predictors, and Impact on Survival of Left Ventricular Systolic Dysfunction and Recovery in Advanced Cancer Patientses_PE
dc.typeinfo:eu-repo/semantics/articlees_PE
dc.identifier.eissn1879-1913-
dc.identifier.journalAmerican Journal of Cardiologyes_PE
dc.description.peer-reviewRevisión por pareses_PE
All Items in UPC are protected by copyright, with all rights reserved, unless otherwise indicated.